Matinas BioPharma (MTNB) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 13, 2019 6:30 AM EST Initiated pre-screening of patients for Phase 2 ENHANCE-IT study of MAT9001 against Vascepa®. Enrollment to commence Q1 2020, with topline data expected H2 2020  NIH-funded Phase 2 EnACT trial of MAT2203 in cryptococcal meningitis initiated in October Management to host conference call today, Wednesday, November 13th, at 8:00 a.m. ET Â
BEDMINSTER, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:... More
